The introduction of selective cyclooxygenase-2 (COX-2) inhibitors, a group of NSAIDs, has resulted in arapid increase in the number of people exposed to NSAIDs. Many patients who would otherwise not have used an NSAID are now using COX-2 inhibitors without a corre-sponding decrease in the use of more traditional nonselec-tive NSAIDs.1,2 Although COX-2 inhibitors have been found to be associated with a lower risk of significant adverse gas-trointestinal events than have traditional nonselective NSAIDs at the level of the individual patient,3,4 recent evi-dence suggests that the market expansion created by COX-2 inhibitors may increase rates of hospital admissions be-cause of upper gastrointestinal (GI) bleeding at the popula-tion level.5 The degree of adoption of a new drug into clinical practice is driven, in part, by decisions of public and private insurers to provide coverage. For example, COX-2 inhibitors wer

Similar works

Full text

oaioai:CiteSeerX.psu: time updated on 10/29/2017

This paper was published in CiteSeerX.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.